Brief: Wuhan Yzy Biopharma Co Says NDA For M701 Accepted By NMPA For Treatment Of Malignant Ascites
07/05/2026 10:34
May 7 (Reuters) - Wuhan YZY Biopharma Co Ltd 2496.HK: NDA FOR M701 ACCEPTED BY NMPA FOR TREATMENT OF MALIGNANT ASCITES Further company coverage: 2496.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Wuhan YZY Biopharma
See all newsBrief: HKEX Says Trading In Wuhan Yzy Biopharma H Shares Halted
Brief: Wuhan Yzy Biopharma Co Says NDA For M701 Accepted By NMPA For Treatment Of Malignant Ascites
Brief: Wuhan Yzy Biopharma Says M701 Receives IND Approval From FDA
Brief: Wuhan YZY Biopharma Says Wuhan Yiruide To Buy Land Use Right And Building
Brief: Wuhan Yzy Biopharma Says Y225 Receives IND Approval From NMPA